• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Alpine Immune Sciences Inc. (Amendment)

    2/14/24 3:07:47 PM ET
    $ALPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALPN alert in real time by email
    SC 13G/A 1 schedule13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     

     
    Alpine Immune Sciences, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock
     
     
    (Title of Class of Securities)
     

     
    02083G100
     
     
    (CUSIP Number)
     

     
    December 31, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare Master Fund, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Cayman Islands

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    2,550,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    2,550,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    4.39%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
     
    Cormorant Global Healthcare GP, LLC
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    2,550,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    2,550,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    4.39%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    OO (Limited Liability Company)
     

    1
    Names of Reporting Persons.
     
    Cormorant Asset Management, LP
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    2,550,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    2,550,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    4.39%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    PN (Partnership)
     


    1
    Names of Reporting Persons.
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    0 shares
    6  Shared Voting Power
     
    2,550,000 shares
    Refer to Item 4 below.
    7  Sole Dispositive Power
     
    0 shares
    8  Shared Dispositive Power
     
    2,550,000 shares
    Refer to Item 4 below.

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    2,550,000 shares
     
    Refer to Item 4 below.
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    4.39%
    Refer to Item 4 below.
     
    12
    Type of Reporting Person (See Instructions)
     
    IN (Individual)
     

    Item 1.
    (a)
    Name of Issuer
     
    Alpine Immune Sciences, Inc.
     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    188 East Blaine Street, Suite 200, Seattle, WA 98102

    Item 2.
    (a)
    Name of Person Filing
     

    Cormorant Global Healthcare Master Fund, LP
    Cormorant Global Healthcare GP, LLC
    Cormorant Asset Management, LP
    Bihua Chen
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
    (c)
    Citizenship
     
     
    Cormorant Global Healthcare Master Fund, LP - Cayman Islands
    Cormorant Global Healthcare GP, LLC - Delaware
    Cormorant Asset Management, LP - Delaware
    Bihua Chen - United States
     
    (d)
    Title of Class of Securities
     
    Common Stock
     
    (e)
    CUSIP Number
     
    02083G100


    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
    (g)
    [ ]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)          Amount Beneficially Owned***

    The information set forth in Row 9 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(a) for each such Reporting Person.

    (b)          Percent of Class***

    The information set forth in Row 11 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(b) for each such Reporting Person.

    (c)          Number of shares as to which such person has: ***

    (i)          sole power to vote or to direct the vote

    (ii)          shared power to vote or to direct the vote

    (iii)          sole power to dispose or to direct the disposition of

    (iv)          shared power to dispose or to direct the disposition of

    The information set forth in Rows 5 through 8 on the cover page for each Reporting Person is hereby incorporated by reference into this Item 4(c) for each such Reporting Person.

    *** Shares reported herein for Cormorant Asset Management, LP represent shares which are beneficially owned by Cormorant Global Healthcare Master Fund, LP (the “Master Fund”), as reported herein. Cormorant Global Healthcare GP, LLC serves as the general partner of the Master Fund. Cormorant Asset Management, LP serves as the investment manager to the Master Fund. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC and the general partner of Cormorant Asset Management, LP. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or her pecuniary interest therein.
    The percentages reported herein with respect to the Reporting Persons’ holdings are calculated based upon a statement in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, as filed with the Securities and Exchange Commission on November 14, 2023, that there were 58,097,961 shares of Common Stock of the Issuer outstanding as of November 9, 2023.

    Item 5.
    Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    Exhibits                          Exhibit
    99.1                  Joint Filing Agreement by and among the Reporting Persons, incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons with
    the Securities and Exchange Commission on October 23, 2023.

    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
    February 14, 2024

     
    CORMORANT GLOBAL HEALTHCARE MASTER
     
    FUND, LP

     
    By:
    Cormorant Global Healthcare GP, LLC
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    CORMORANT GLOBAL HEALTHCARE GP, LLC
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    CORMORANT ASSET MANAGEMENT, LP
     
    By:
    Cormorant Asset Management GP, LLC
     
     
    its General Partner
     
     
     
     
    By:
    /s/ Bihua Chen
     
    Bihua Chen, Managing Member
     
     
     
     
    /s/ Bihua Chen
     
    Bihua Chen


    Get the next $ALPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALPN

    DatePrice TargetRatingAnalyst
    4/9/2024$55.00Buy
    Guggenheim
    2/15/2024$44.00Outperform
    Wolfe Research
    10/18/2023$18.00Buy
    Berenberg
    10/17/2023$18.00Buy
    Berenberg
    10/5/2023$19.00Outperform
    RBC Capital Mkts
    6/26/2023$14.00Outperform
    Oppenheimer
    1/19/2023$17.00Overweight
    Morgan Stanley
    11/21/2022$15.00Outperform
    SVB Leerink
    More analyst ratings

    $ALPN
    Financials

    Live finance-specific insights

    See more
    • Vertex Enters Into Agreement to Acquire Alpine Immune Sciences

      - Alpine is a clinical stage biotechnology company focused on discovering and developing innovative, protein-based immunotherapies - - Alpine's lead product, povetacicept, demonstrated best-in-class potential in patients with IgA nephropathy (IgAN); Phase 3 to initiate in H2 2024 - - Povetacicept holds promise as a pipeline-in-a-product, with clinical studies in additional serious diseases underway - - Alpine's protein engineering and immunotherapy expertise augments Vertex's toolbox and capabilities - - Vertex to host investor call today, April 10, at 4:30 pm ET - Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a biotechnology com

      4/10/24 4:01:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences to Report Fourth Quarter and Full Year 2023 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the Company will release fourth quarter and full year 2023 financial results on Monday, March 18, 2024, after the close of market. The Company will host a corresponding conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on the same day. Conference Call and Webcast Information The link to the webcast will be available in the investor relations section of the Company's website at https://ir.alpineimmunesciences.com/events and a replay will be available on the Company's website for 90 days

      3/7/24 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Presents Initial Clinical Data on Povetacicept in Autoimmune Glomerulonephritis in a Late-Breaking Poster Session at the American Society of Nephrology Kidney Week 2023

      -- Low-dose povetacicept (80 mg administered once every four weeks) was well tolerated during subcutaneous administration and reduced UPCR by greater than 50% in IgA nephropathy -- -- Higher dose povetacicept (240 mg) administered once every four weeks currently being explored -- -- Based on this data Alpine will now seek to begin a pivotal phase 3 IgAN study in the second half of 2024 -- -- Company to host virtual investor call and webcast today at 4:30 pm ET with James Tumlin, M.D. and Jonathan Barratt, Ph.D., FRCP -- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammator

      11/2/23 9:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Announces Appointment of Wolfgang Dummer, M.D., Ph.D., as Chief Medical Officer and Grant under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of Wolfgang Dummer, M.D., Ph.D., to Chief Medical Officer effective October 2, 2023. He succeeds Andrew Sandler, M.D., who will transition responsibilities to Dr. Dummer through the remainder of the year. "Wolfgang is a highly accomplished drug developer with deep expertise in rare disease, immunology, and immunotherapy. His experience working across all phases of clinical development through regulatory approval will be important as we continue to advance our pipeline of new therapie

      10/4/23 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Announces Appointment of M. Christina Yi as Chief Technology Officer and Grant under Nasdaq Listing Rule 5635(c)

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the appointment of M. Christina Yi to Chief Technology Officer effective August 21, 2023. Ms. Yi has more than 25 years of biopharmaceuticals leadership experience, including manufacturing, quality, and supply chain. She succeeds Wayne Gombotz, Ph.D., who will retire in August. "Christina is an accomplished industry leader and will be a key addition to our executive team as we prepare for a broad development plan for povetacicept. Her expertise and leadership will be important to Alpine as we contin

      8/22/23 4:30:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Peetz Christopher returned 1,900 shares to the company (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:14:39 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Hernday Natasha

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:13:47 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Drappa Jorn

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      5/20/24 8:12:51 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alpine Immune Sciences Inc.

      15-12G - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/30/24 9:12:26 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:07 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Alpine Immune Sciences Inc.

      EFFECT - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Filer)

      5/24/24 12:15:33 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 4:49:22 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      5/21/24 10:21:59 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Alpine Immune Sciences Inc. (Amendment)

      SC 13D/A - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Subject)

      4/30/24 4:20:00 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ALPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Frazier Life Sciences Appoints Biotech Innovators Mitchell H. Gold and Stanford L. Peng as Venture Partners

      Frazier Life Sciences (FLS), a longstanding investment firm focused on innovative therapeutics, today announced the appointments of Mitchell H. Gold, M.D., and Stanford L. Peng, M.D., Ph.D., as Venture Partners. "We believe Mitch and Stanford bring exceptional leadership and experience that will elevate our ability to create and nurture breakthrough biopharmaceutical companies," said Jamie Topper, M.D., Ph.D., Managing Partner at FLS. "Mitch's history of building transformative companies, his relentless pursuit of scientific excellence and his proven ability to identify transformative scientific and investment opportunities make him a valuable addition to our team. Similarly, Stanford's p

      1/9/25 8:00:00 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Attovia Therapeutics Announces Election of Mitchell Gold and Angie You to Board of Directors

      FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades of industry leadership experience, including early- and late-stage therapeutic development and commercialization. "I am delighted to welcome Mitch and Angie to the team. They are industry leaders with a proven track record of success in building both public and private biopharma companies. As Attovia looks toward our next stage of growth and drives our mission of bringing forward first-in-c

      7/9/24 7:30:00 AM ET
      $ALPN
      $ORIC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alpine Immune Sciences Reports First Quarter 2024 Financial Results

      Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) and Alpine announced that the companies had entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Directors and is anticipated to close in the second quarter of 2024. First Quarter 2024 Financial Results Cash Position and Runway: As of March

      5/9/24 4:00:00 PM ET
      $ALPN
      $VRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Alpine Immune Sciences with a new price target

      Guggenheim initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $55.00

      4/9/24 7:38:17 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wolfe Research initiated coverage on Alpine Immune Sciences with a new price target

      Wolfe Research initiated coverage of Alpine Immune Sciences with a rating of Outperform and set a new price target of $44.00

      2/15/24 6:19:18 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berenberg initiated coverage on Alpine Immune Sciences with a new price target

      Berenberg initiated coverage of Alpine Immune Sciences with a rating of Buy and set a new price target of $18.00

      10/18/23 7:51:16 AM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALPN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Decheng Capital Global Healthcare Fund (Master), Lp bought $4,687,500 worth of shares (375,000 units at $12.50) (SEC Form 4)

      4 - ALPINE IMMUNE SCIENCES, INC. (0001626199) (Issuer)

      11/14/23 5:36:42 PM ET
      $ALPN
      Biotechnology: Pharmaceutical Preparations
      Health Care